Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
How do you approach metastatic colon cancer that has been refractory to multiple lines of systemic therapy though maintaining an adequate PS for additional treatment?
How do you approach a decision to retry a previously failed therapy if patient does not wish to pursue a clinical trial? Does sidedness (left or right), BRAF/RAS status, or prior biologic exposure also factor into this decision?
Answer from: Medical Oncologist at Academic Institution
Unfortunately, if the patient has seen all standard therapies, including third/fourth line TAS-102 and regorafenib, then the only option is clinical trials. Molecular profiling could also reveal less common (and less "standard" tested) molecular abnormalities that could offer more options, such as H...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
If b-raf V600E mutated, consider the Beacon regimen of cetuximab, encorafenib and binimetinib based on the data presented at GI ASCO 2018. Activity is good and I have been able to get it covered for patients.
Answer from: Medical Oncologist at Community Practice
The Beacon study really did not include patients which had exhausted therapy options.
50% had received only 1 line and the rest 2 lines.
It very difficult given this population to interpret the activity of other EGFR combinations, particularly if the majority had not received...